Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. BCPT policy for experimental and clinical studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Active chlordiazepoxide metabolites in a patient needing life support after treatment of alcohol abstinence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Polypharmacy in schizophrenia

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Active chlordiazepoxide metabolites in a patient needing life support after treatment of alcohol abstinence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pulmonary administration of remdesivir in the treatment of COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Access and Use of Device-Aided Therapies for Parkinson's Disease in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The present clinical trial investigated the impact of selected SNPs in CES1 on the metabolic activity of the enzyme. For this purpose, we used methylphenidate (MPH) as a pharmacological probe and the d-RA/d-MPH (metabolite/parent drug) ratios as a measure of enzymatic activity. This metabolic ratio (MR) was validated against the AUC ratios (AUC d -RA/AUC d -MPH). CES1 SNPs from 120 volunteers were identified, and 12 SNPs fulfilling predefined inclusion criteria were analysed separately, comparing the effect of each genotype on the metabolic ratios. The SNP criteria were as follows: presence of Hardy-Weinberg equilibrium, a minor allele frequency ≥ 0.01 and a clearly interpretable sequencing result in at least 30% of the individuals. Each participant ingested 10 mg of racemic methylphenidate, and blood samples were drawn prior to and 3 hours after drug administration. The SNP analysis confirmed the considerable impact of rs71647871 (G143E) in exon 4 on drug metabolism. In addition, three volunteers with markedly lower median MR, indicating decreased CES1 activity, harboured the same combination of three SNPs in intron 5. The median MR for these SNPs was 8.2 for the minor allele compared to 16.4 for the major alleles (P = 0.04). Hence, one of these or the combination of these SNPs could be of clinical significance considering that the median MR of the G143E group was 5.4. The precise genetic relationship of this finding is currently unknown, as is the clinical significance.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
Vol/bind125
Udgave nummer1
Sider (fra-til)54-61
Antal sider8
ISSN1742-7843
DOI
StatusUdgivet - jul. 2019

ID: 56746152